

Buslera®

Busulfan 60 mg/10 ml Vial Containing Concentrated Solution for IV Infusion

Ocladra®

Cladribine 2 mg/ml Vial Containing Injectable Solution



Active Ingredient

Busulfan 60 mg/10 ml

Treatment Area

Antineoplastic Agent / Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT)

Presentation

60 mg/10 ml, 1 vial per box

Launch Date

2014

Active Ingredient

Cladribine 2 mg/ml

Treatment Area

Antineoplastics, Antimetabolite / Hairy Cell Leukemia

Presentation

10 mg/5 ml, 1 vial per box

Launch Date

2014



Beastin®

Bendamustine HCl 25 mg and 100 mg Lyophilized Powder for Solution for Infusion

Votron®

Palonosetron HCl 250 µg/5 ml Solution for IV Injection



Active Ingredient	Bendamustine Hydrochloride
Treatment Area	Antineoplastic, Alkylating Agent / Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma, Multiple Myeloma
Presentation	25 mg and 100 mg vial
Launch Date	2014

Active Ingredient	Palonosetron HCl 250 µg/5ml
Treatment Area	Anti-emetic/ Anti-vomiting and Anti-nausea agent used in chemotherapy treatments
Presentation	250 µg/5 ml, 1 vial per box
Launch Date	2012



Biemib®

Bortezomib 3,5 mg IV/SC Powder for Solution for Injection



Active Ingredient

Bortezomib

Treatment Area

Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
Multiple Myeloma

Presentation

3,5 mg

Launch Date

2015

Active Ingredient

Letrozole

Treatment Area

Antineoplastic Agent/ Breast Cancer

Presentation


2,5 mg, 30 Film-Coated Tablets

Launch Date

2009

Letroks®

Letrozole 2,5 mg Film-Coated Tablets



Bimexet®

Pemetrexed 500 mg Lyophilized Powder for IV Injection



Active Ingredient

Pemetrexed

Treatment Area

Folic Acid Analogues/ Lung Cancer

Presentation

50 mL Vial / Box

Launch Date

2019

Desibem®

Decitabine 50 mg Powder for Solution for IV Injection



Active Ingredient

Decitabine

Treatment Area

Antineoplastic agents, antimetabolites,
pyrimidine analogs/ Treatment of Leukemia

Presentation

10 mL Vial/box

Launch Date

2019

Biemexol®

Iohexol 300/350 mg/ml Solution for Injection



Active Ingredient

Iohexol 300 mg/ml and 350 mg/ml

Treatment Area

Diagnostic Imaging Agent/CT Imaging; Angiography etc.

Presentation

300 mg/ml in 50 and 100 vials
350 mg/ml 50, 100 and 200 vials

Launch Date

2015

Gadodiem®

Gadodiamide 287 mg/ml Solution for IV Injection



Active Ingredient

Gadodiamide 287 mg/ml

Treatment Area

Diagnostic Contrast Agent, Magnetic Resonance Imaging (MRI)

Presentation

10, 15, 20 ml vials

Launch Date

2015

CONTRAST MEDIA

Gadonans

Gadobutrol 1mmol/mL Solution for Injection



Active Ingredient

Gadobutrol

Treatment Area

Magnetic Resonance Imaging

Presentation

7,5 mL / 15 mL / 30 mL

Launch Date

2021

FIRST REMEDY, ONLY REMEDY

Emaray®

Gadopentetate Dimeglumine Solution for IV Injection



Active Ingredient

Gadopentetate Dimeglumine 469,01 mg/ml

Treatment Area

Magnetic Resonance Imaging (MRI), Diagnostic Contrast Agent

Presentation

10, 15, 20 ml vials

Launch Date

2012

Btiray®

Iopamidol 300/370 Solution for Injection



Active Ingredient

300 mg/ml - 612 mg Iopamidol
370 mg/ml - 755 mg Iopamidol

Treatment Area

Diagnostic Imaging Agent/ CT Imaging; Angiography etc.

Presentation

300 mg/ml in 50 ml, 100 ml vials
370 mg/ml in 50 ml, 100 ml, 200 ml vials

Launch Date

2012

Mrsacin[®]

Tigecycline 50 mg Vial Containing Lyophilized Powder for IV Infusion



Active Ingredient

Tigecycline 50 mg

Treatment Area

Antibiotic/Antibacterial for systemic use

Presentation


50 mg, 10 vials per box

Launch Date

2014

Trozasin[®]

Voriconazole 200 mg Powder for Solution for IV Infusion



Active Ingredient

Voriconazole 200 mg

Treatment Area

Antifungal, Systemic/Invasive Aspergillosis; Nonneutropenic Candidemia; Disseminated Candida Infections etc.

Presentation

200 mg, 1 vial per box

Launch Date

2017

Kolistate®

Colistimethate Sodium 4,500,000 IU Powder for IM/IV Injection and Inhalation Solution



Active Ingredient

Colistimethate Sodium 4,500,000 IU

Treatment Area

Anti-Infectives-Other Antibacterials / Selected Aerobic Gram-Negative Pathogens in Patients with Limited Treatment Options

Presentation

1 vial powder and 1 ampoule solvent per box

Launch Date

2017

Active Ingredient

Iron Sucrose 100 mg/5 ml

Treatment Area

Haematinics/ Iron Deficiency Anemia in Chronic Kidney Disease

Presentation

100 mg/5 ml x 5 ampoules per box

Launch Date

2013

Iron Sucrose 100 mg/5 ml Solution for IV Infusion and Injection



Calsipar®

Paricalcitol 10 mcg/2 ml – 5 mcg/ml Solution for Injection

Biemparin®

Heparin Sodium 25000 IU/5 ml Solution for Injection



Active Ingredient

Paricalcitol 10 mcg/2 ml – 5 mcg/ml

Treatment Area

Systemic hormonal preparations - Anti-parathyroid agents / Its primary use in medicine is in the treatment

Presentation

10 mcg/2 ml - 5 mcg/ml, 5 ampoules per box

Launch Date

2017

Active Ingredient

Heparin Sodium 25000 IU/5 ml

Treatment Area

Anticoagulant Therapy

Presentation

1 vial per box

Launch Date

2017



Lokaril®

Lidocaine/Prilocaine Cream 5%



Active Ingredient

Lidocaine/Prilocaine 5%

Treatment Area

Local anaesthetics / Dermal anaesthesia, intravenous catheter insertion, blood sampling, superficial surgical procedures and topical anaesthesia of leg ulcers for cleansing or debridement

Presentation

10 g tube per box

Launch Date

2017

Sedozolam®

Midazolam 15 mg/3 ml - 5 mg/5 ml Solution for Injection or Infusion



Active Ingredient

Midazolam 15 mg/3 ml - 5 mg/5 ml

Treatment Area

Hypnotics and sedatives / Conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia, Anaesthesia

Presentation

15 mg/3 ml - 5 mg/5 ml, 5 ampoules per box

Launch Date

2017

Biemefrin®

Norepinephrine Bitartrate 4 mg/4 ml Solution
for IV Infusion



Active Ingredient

Norepinephrine Bitartrate 4 mg/4 ml

Treatment Area

Acute Hypotension, Adrenergic Agent

Presentation

4 mg/4 ml x 10 ampoules per box

Launch Date

2014

Pargicyl®

Apomorphine HCl 50 mg/5 ml – 20 mg/2 ml Solution
for Injection

Active Ingredient

Apomorphine HCl 50 mg/5 ml – 20 mg/2 ml

Treatment Area

Nervous System - Dopamine Agonists / Parkinson's Disease

Presentation

50 mg/5 ml – 20 mg/2 ml, 5 ampoules per box

Launch Date

2017

Pargicyl

20 mg/2ml Solution for Injection

Apomorphine HCl

Sterile

Pargicyl 2ml ampoule contains 20 mg Apomorphine hydrochloride (equivalent to 20 mg Apomorphine). Each 2 ml ampoule contains 50 mg Apomorphine hydrochloride in 50 mg solution. It contains sodium metabisulfite (E223), hydrochloric acid, concentrated for pH adjustment, sodium hydroxide for pH adjustment and water for injection as excipients (sodium chloride buffer for more information).

biem

2 ml x 5 A

Pargicyl

50 mg/5ml Solution for Injection

Apomorphine HCl

Sterile

Pargicyl 5ml ampoule contains 50 mg Apomorphine hydrochloride (equivalent to 50 mg Apomorphine). Each 5 ml ampoule contains 100 mg Apomorphine hydrochloride in 100 mg solution. It contains sodium metabisulfite (E223), hydrochloric acid, concentrated for pH adjustment, sodium hydroxide for pH adjustment and water for injection as excipients (sodium chloride buffer for more information).

biem

5 ml x 5 Ampoules

Enfluat®

Ketorolac Tromethamine 0,4% Sterile Ophthalmic Eye Drops



Active Ingredient

Ketorolac Tromethamine 0,4%

Treatment Area

Nonsteroidal anti-inflammatory drug for ophthalmic use

Presentation

0.4% Sterile ophthalmic solution 5 ml per box

Launch Date

2014

Zaridinex®

Ofloxacin 0,3% Sterile Ophthalmic Eye Drops



Active Ingredient

Ofloxacin 0.3%

Treatment Area

Anti-infective quinolone antibiotics/ Bacterial eye infection

Presentation


0.3% Sterile ophtalmic solution 5 ml per box

Launch Date

2014

Gloger®

Brimonidine Tartarate 0.15% Sterile Eye Drops



Active Ingredient

Brimonidine Tartarate

Treatment Area

Sympathomimetics used in the treatment of ophthalmic-glaucoma

Presentation

5 mL Sterile Drop/box

Launch Date

2018

Conjiten®

**Ketotifen Hydrogen Fumarate
0.025% Sterile Eye Drops**



Active Ingredient

Ketotifen Hydrogen Fumarate 0.025%

Treatment Area

Antiallergic Conjunctivitis

Presentation

0.025% Sterile Eye Drops 5 ml per box

Launch Date

2018

Moxibiem®

Moxifloxacin 0.5% Sterile Eye Drops

Under Preparation



Active Ingredient

Moxifloxacin 0.5%

Treatment Area

Ophthalmologies

Presentation

5 ml Sterile Eye Drops per box

Launch Date

2019

Erbinna®

Omeprazole Sodium 40 mg Powder for Solution for IV Infusion



Active Ingredient

Omeprazole Sodium 40 mg

Treatment Area

Proton Pump Inhibitors(PPI) / Gastroesophageal Reflux Disease, Peptic Ulcer Disease and Zollinger-Ellison Syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk.

Presentation

1 vial powder and 1 ampoule solvent per box

Launch Date

2017



biem

Turgut Reis Street No:21 Ankara/Turkey
Tel: +90 (312) 230 29 29 Fax: +90 (312) 230 68 00
export@biemilac.com.tr
www.biemilac.com.tr

DESIGNED BY DEFNE GÖKÇE

Defne